You are here

Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91018C00036
Agency Tracking Number: N43AI180036
Amount: $41,693.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: N/A
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
MISSOULA, MT 59802-4906
United States
DUNS: 803607154
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Juhienah Khalaf
 (785) 727-3212
Business Contact
 Juhienah Khalaf
Phone: (785) 727-3212
Research Institution

This pilot study is aimed at judging the efficacy of the lead compound with a clinically relevant allergenThe relevant allergen chosen for this study is the house dust mite Dermatophagoides pteronyssinus allergenDer pLoToxTM Natural Der pfrom Indoor Biotechnologies with a low endotoxin contentEUgWe are selecting this allergen because our team has extensive prior experience with this allergen in mouse studies and has previously determined the doses required for sensitization and challengesAlternativelywe could also use the timothy grass allergen Phleum pratense allergenLoToxTM Recombinant Phl pfrom Indoor Biotechnologiesas a more relevant allergen for allergic rhinitisbut this would require additional dose response studies to determine the amounts of allergen required for both sensitization and challenges in the murine systemWe propose to investigate the efficacy of one versus two treatments of lead compoundtwo different dosesin the Der pallergen model

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government